Sirolimus Pill

Phase 2Small molecule

MMasonic Cancer Center, University of Minnesota

Sirolimus Pill is one of 7 small molecule programs targeting Acute Myelogenous Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myelogenous LeukemiaRecruiting

Acute Myelogenous LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in Acute Myelogenous Leukemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

2 2

Cellcept

Roche

Phase 2

2 3

Zyloprim

Jazz Pharmaceuticals

Phase 2

1 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 5

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 6

ICP-248

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 1

1 7

Sirolimus Pill

MMasonic Cancer Center, University of Minnesota

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Acute Myelogenous Leukemia

NCT05805605

Clinical

Trials by Indication[1]

Acute Myelogenous Leukemia1 trial

Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT05805605·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sirolimus Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sirolimus Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sirolimus Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMasonic Cancer Center, University of Minnesota

Sirolimus Pill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Acute Myelogenous Leukemia1 trial

References

Drug Info

Quick Facts

Related News